Vaxcyte Financials - Benzinga

Vaxcyte Inc

PCVXNASDAQ

Trade with Public

Trade with Public

$58.69

2.484.41%

最終更新: Sep 28, 2:50 PM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Vaxcyte Financials

Vaxcyte (PCVX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Vaxcyte Q2 EPS $(1.97) Beats $(2.22) Estimate

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.97) per share which beat the analyst consensus estimate of $(2.22) by 11.26 percent. This is a 61.48 percent decrease over losses of $(1.22) per share from the same

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(2.30) per share which missed the analyst consensus estimate of $(1.82) by 26.37 percent. This is a 121.15 percent decrease over losses of $(1.04) per share from the

Benzinga Newsdesk

PRO
Vaxcyte Q4 EPS $(1.80) Misses $(1.56) Estimate

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.80) per share which missed the analyst consensus estimate of $(1.56) by 15.38 percent. This is a 76.47 percent decrease over losses of $(1.02) per share from the

Benzinga Newsdesk

Earnings Scheduled For February 24, 2026

Benzinga Insights

Earnings Outlook For Vaxcyte

Benzinga Insights

© 2026 Benzinga | All Rights Reserved